Bristol Myers Squibb is facing a bit of an identity crisis. CEO Chris Boerner is nearly two and a half years into his tenure, with

Pfizer’s positive Phase 3 data in multiple myeloma: The company’s Elrexfio produced a “statistically significant and clinically meaningful improvement” in progression-free survival in patients with

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Biogen is still looking at deals even after earmarking $5.6 billion to buy Apellis Pharmaceuticals earlier this month. “Most of what we’re going to be

Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry’s vigorous spring shopping spree. The Italian pharma will